ST2825, independent of MyD88, induces reactive oxygen species-dependent apoptosis in multiple myeloma cells

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Myeloid differentiation factor 88 (MyD88) is a key regulator of nuclear factor kappa B (NF-κB) and is implicated in lymphoid malignancies.
• The role of MyD88 in multiple myeloma (MM), a plasma cell disorder, was previously unexplored.

Purpose of the Study:

• To investigate the role and therapeutic potential of MyD88 in multiple myeloma.
• To determine the correlation between MyD88 expression and patient survival in MM.

Main Methods:

• Bioinformatic analysis of publicly available datasets to assess MyD88 expression and gene alteration in MM.
• In vitro treatment of MM cells with ST2825, a specific MyD88 inhibitor.
• Assessment of reactive oxygen species (ROS) generation and apoptosis induction.

Main Results:

• Higher MyD88 expression significantly correlated with poor survival in MM patients.
• MyD88 gene alterations were rare in MM, unlike in Waldenstrom's macroglobulinemia (WM).
• ST2825 suppressed MM cell growth, induced apoptosis, and increased intracellular ROS.
• N-acetyl-l-cysteine, a ROS scavenger, reduced ST2825-induced apoptosis, indicating ROS-dependent cell death.

Conclusions:

• ST2825 induces apoptosis in MM cells through a ROS-dependent mechanism.
• MyD88 inhibition represents a potential therapeutic strategy for multiple myeloma.
• This study elucidates MyD88's pathological role in MM and suggests novel treatment avenues.